Value proposition

A novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line)

PDC*line Pharma is a clinical-stage Biotechnology company that develops a new class of potent, off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line). Based on a robust preclinical package and a first-in-human phase Ib in melanoma, PDC*line Pharma reported promising Phase I/II results in lung cancer (PDC*lung) in 2024. Preparations are now underway for a randomized Phase II trial in lung cancer, and a Phase Ib trial in colorectal cancer with neoantigens (PDC*neo). The company has raised €61M in equity and non-dilutive funding and signed a €108M licensing deal in Asia with the Korean pharmaceutical company, LG Chem Life Science.

Cancer immunotherapy, Therapeutic vaccines, Clinical development, Plasmacytoid Dendritic Cells, and neoantigens